Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
DexCom Director Mark G. Foletta reported significant insider trading activity through a pre-planned 10b5-1 sale. On June 16, 2025, Foletta's Family Trust sold 2,750 shares at a weighted average price of $83.129 per share, executed through multiple trades ranging from $82.635 to $83.61.
Following the transaction, Foletta maintains beneficial ownership of:
- 56,621 shares held indirectly through The Foletta Family Trust DTD 1/30/2015
- 5,731 unvested restricted stock units granted on May 8, 2025, which will vest on the earlier of the one-year anniversary or DexCom's 2026 Annual Meeting
The sale was executed under a 10b5-1 trading plan adopted by the Trust on March 13, 2025, designed to enable orderly disposition of shares. This transaction demonstrates planned insider selling activity while maintaining substantial equity position in the company.
On June 16, 2025, DexCom, Inc. (DXCM) Executive Vice President & Chief Legal Officer Michael Jon Brown sold 500 shares of common stock at $82.80 per share, according to a Form 4 filed on June 18, 2025. The trade was executed under a Rule 10b5-1 trading plan adopted on February 21, 2025, which pre-schedules transactions to reduce the appearance of information-based trading.
Following the sale, Brown’s beneficial ownership stands at 95,102 shares, including 86,490 unvested restricted stock units that vest through 2028. No derivative security activity was reported and there are no indications of changes in Brown’s role or corporate strategy. The 500-share sale represents roughly 0.5 % of his reported holdings and is immaterial relative to DexCom’s total public float.